Early real-life evaluation of the efficacy of esketamine in resistant depressive disorder

INTRODUCTION: The efficacy and of current antidepressants is insufficient. Esketamine, a new antidepressant administered by nasal route, is available since 2019 in the management of resistant characterized depressive episodes. OBJECTIVES: To evaluate the response profile of patients to Esketamine in...

Descripción completa

Detalles Bibliográficos
Autores principales: Faisant, S., Crublet, P., Bellay, R., Langrée, B., Marie, N., Rojo-Bouton, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2022
Materias:
Abstract
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567366/
http://dx.doi.org/10.1192/j.eurpsy.2022.1417

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567366/
http://dx.doi.org/10.1192/j.eurpsy.2022.1417

Ejemplares similares